Clinical trials
Aggression clinical trials
Below are recruiting aggression clinical trials, each written for real people, not researchers. We’re tracking 88 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03938987RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive aggressive lymphoma or ALL
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
Calgary, AlbertaAges 2–70 - NCT07398170Recruiting
Searching for tumor cells in fluid for recurrent meningioma
This study looks for tumor cells in your blood or spinal fluid to see if they can help track aggressive meningiomas that have come back. It may help doctors understand your cancer better and guide future treatments.
Montpellier, FranceAges 18 years+ - NCT04436081RecruitingPhase 2
CBD oil without THC for agitation in Alzheimer’s dementia
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
Norfolk, VirginiaAges 50–90 - NCT04472338Recruiting
Prostate cancer screening for people with higher genetic risk
This study looks at prostate cancer screening for people who may be at higher risk because of a specific inherited (genetic) change. It may help your care team find the best screening approach to catch aggressive prostate cancer earlier.
Duarte, CaliforniaAges 40 years+ - NCT04610697Recruiting
Cognitive training for people in forensic mental health care
This trial studies whether a structured “cognitive remediation” program (training thinking skills) can help people receiving care on a forensic treatment unit. It may benefit those who want support improving attention, memory, or problem-solving as part of their treatment.
Ottawa, OntarioAges 18–55 - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Birmingham, AlabamaAges 18 years+ - NCT05257629RecruitingPhase 3
Aggressive smoking quit program after heart problems
This trial tests whether a strong quit plan using varenicline (a quit pill) plus nicotine e-cigarettes, along with counseling, helps people stop smoking after a recent heart-related event. It’s aimed at people who want to quit and can safely stay involved for about a year.
New Westminster, British ColumbiaAges 18 years+ - NCT05500391RecruitingPhase 2
Testing whether remote nurse monitoring works like in-person checks
This Phase 2 study compares two ways of checking your cancer follow-up: a doctor or nurse visits in person versus remote monitoring by phone and imaging. The goal is to see whether remote monitoring can safely replace or match in-person care for certain low-risk cancers and after surgery.
AmiensAges 18 years+ - NCT05543681RecruitingPhase 2
Study drug for agitation in Alzheimer’s dementia with caregiver support
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
Maitland, FloridaAges 60 years+ - NCT05674825RecruitingPhase 1/Phase 2
Personalized treatment using tumor test results for aggressive cancers
This early-phase study tests whether a personalized cancer treatment plan based on your tumor’s test results can help people with aggressive cancers that are hard to treat. It may be an option if standard treatments didn’t work, aren’t possible for you, or you have few treatment choices.
Milwaukee, WisconsinAges 18 years+ - NCT05765864Recruiting
Study of self-harm in at-risk teens
This study looks at self-harm and thoughts/behaviors related to safety in teenagers who are considered at higher risk. It may help researchers better understand what supports are needed for teens who self-harm without wanting to die.
LjubljanaAges 13–18 - NCT05793034Recruiting
Study factors that predict survival after aggressive meningioma surgery
This study looks at people who had surgery for more aggressive meningiomas (grade 2 or 3) and tries to learn what factors relate to survival. The results may help doctors better predict outcomes for future patients.
RomeAges 18 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Irvine, CaliforniaAges 18 years+ - NCT05895513RecruitingPhase 2
Pimavanserin trial for aggression and social thinking
This Phase 2 trial tests pimavanserin, a medication that may affect brain signals, to see if it can reduce aggression and improve social thinking in people with intermittent explosive disorder (IED) or a history of aggressive behavior. If you qualify, you’ll be screened with medical tests and questionnaires and must meet medication and safety rules to participate.
Columbus, OhioAges 21–55 - NCT05974696Recruiting
Registry for aggressive pituitary tumors (Aggressive PitNETs)
This study is a research registry that collects information from people with aggressive pituitary tumors. It may help researchers better understand these tumors by building a large, shared dataset over time.
LyonAges 18 years+ - NCT05996185RecruitingPhase 2
Study of mogamulizumab plus chemotherapy for T-cell lymphoma
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
New Haven, ConnecticutAges 18 years+ - NCT06085729RecruitingPhase 1/Phase 2
Study of ADI-PEG20 with chemo for aggressive prostate cancer
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT06118567RecruitingPhase 2
Does nitrous oxide help with aggression?
This study tests if a single dose of nitrous oxide (laughing gas) can reduce aggression in people with intermittent explosive disorder (IED). It compares their reactions to healthy volunteers without aggression issues.
Columbus, OhioAges 21–55 - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Philadelphia, PennsylvaniaAges birth–18 years - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07052578Recruiting
Aggressive prostate cancer study with HRR blood test
This study looks at men with aggressive, high-volume metastatic prostate cancer that is still sensitive to hormone therapy. It will analyze a blood test for HRR gene mutations (like BRCA) to help understand treatment patterns.
ArkhangelskAges 18 years+ - NCT07041606Recruiting
A study on advanced endometrial cancer in Russia
This study looks at genetic profiles and first treatments for advanced or aggressive endometrial cancer in women in Russia. It aims to understand how genetic information might guide better treatment choices.
ArkhangelskAges 18 years+ - NCT06534437RecruitingPhase 2
Study of MEN1703 for aggressive B-cell lymphoma
This trial tests a new drug called MEN1703, alone or with another drug (glofitamab), for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if it can help shrink tumors.
Le MansAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+
Hear when a new Aggression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for aggression?
- Yes. Clin2 currently lists 88 recruiting aggression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a aggression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a aggression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.